Merck
  • Home
  • Search Results
  • Validation and pharmacokinetic application of a high-performance liquid chromatographic technique for determining the concentrations of amodiaquine and its metabolite in plasma of patients treated with oral fixed-dose amodiaquine-artesunate combination in areas of malaria endemicity.

Validation and pharmacokinetic application of a high-performance liquid chromatographic technique for determining the concentrations of amodiaquine and its metabolite in plasma of patients treated with oral fixed-dose amodiaquine-artesunate combination in areas of malaria endemicity.

Antimicrobial agents and chemotherapy (2015-04-22)
Olumuyiwa N Adedeji, Oluseye O Bolaji, Catherine O Falade, Odusoga A Osonuga, Olusegun G Ademowo
ABSTRACT

Artemisinin-based combination therapies (ACTs) have been adopted by most African countries, including Nigeria, as first-line treatments for uncomplicated falciparum malaria. Fixed-dose combinations of these ACTs, amodiaquine-artesunate (FDC AQAS) and artemether-lumefantrine (AL), were introduced in Nigeria to improve compliance and achieve positive outcomes of malaria treatment. In order to achieve clinical success with AQAS, we developed and validated a simple and sensitive high-performance liquid chromatography (HPLC) method with UV detection for determination of amodiaquine (AQ) and desethylamodiaquine (DAQ) in plasma using liquid-liquid extraction of the drugs with diethyl ether following protein precipitation with acetonitrile. Chromatographic separation was achieved using an Agilent Zorbax C18 column and a mobile phase consisting of distilled water-methanol (80:20 [vol/vol]) with 2% (vol/vol) triethylamine, pH 2.2, at a flow rate of 1 ml/min. Calibration curves in spiked plasma were linear from 100 to 1,000 ng/ml (r > 0.99) for both AQ and DAQ. The limit of detection was 1 ng (sample size, 20 μl). The intra- and interday coefficients of variation at 150, 300, and 900 ng/ml ranged from 1.3 to 4.8%, and the biases were between 6.4 and 9.5%. The mean extraction recoveries of AQ and DAQ were 80.0% and 68.9%, respectively. The results for the pharmacokinetic parameters of DAQ following oral administration of FDC AQAS (612/200 mg) for 3 days in female and male patients with uncomplicated falciparum malaria showed that the maximum plasma concentrations (C max) (740 ± 197 versus 767 ± 185 ng/ml), areas under the plasma concentration-time curve (AUC) (185,080 ± 20,813 versus 184,940 ± 16,370 h · ng/ml), and elimination half-life values (T 1/2) (212 ± 1.14 versus 214 ± 0.84 h) were similar (P > 0.05).

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
乙腈, anhydrous, 99.8%
Sigma-Aldrich
甲醇, anhydrous, 99.8%
Sigma-Aldrich
三乙基胺, ≥99.5%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
二乙醚, contains 1 ppm BHT as inhibitor, anhydrous, ≥99.7%
Sigma-Aldrich
三乙基胺, ≥99%
Sigma-Aldrich
磷酸, 85 wt. % in H2O, 99.99% trace metals basis
Sigma-Aldrich
二乙醚, anhydrous, ACS reagent, ≥99.0%, contains BHT as inhibitor
Sigma-Aldrich
磷酸, ACS reagent, ≥85 wt. % in H2O
Sigma-Aldrich
三乙基胺, puriss. p.a., ≥99.5% (GC)
Sigma-Aldrich
二乙醚, ACS reagent, anhydrous, ≥99.0%, contains BHT as inhibitor
Sigma-Aldrich
磷酸, ACS reagent, ≥85 wt. % in H2O
Sigma-Aldrich
甲醇, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
乙腈, ACS reagent, ≥99.5%
Sigma-Aldrich
二乙醚, contains BHT as inhibitor, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8%
Sigma-Aldrich
三乙基胺, BioUltra, ≥99.5% (GC)
Sigma-Aldrich
甲醇, Laboratory Reagent, ≥99.6%
Sigma-Aldrich
对乙酰氨基酚, BioXtra, ≥99.0%
Sigma-Aldrich
磷酸 溶液, 85 wt. % in H2O, FCC, FG
Sigma-Aldrich
乙腈 溶液, contains 0.1 % (v/v) formic acid, suitable for HPLC
Sigma-Aldrich
磷酸, crystalline, ≥99.999% trace metals basis
Sigma-Aldrich
乙腈 溶液, contains 0.1 % (v/v) trifluoroacetic acid, suitable for HPLC
Sigma-Aldrich
甲醇, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
乙腈, HPLC Plus, ≥99.9%, poly-coated bottles
Sigma-Aldrich
对乙酰氨基酚, meets USP testing specifications, 98.0-102.0%, powder
Sigma-Aldrich
甲醇, BioReagent, ≥99.93%
Sigma-Aldrich
甲醇, Absolute - Acetone free
Sigma-Aldrich
对乙酰氨基酚, analytical standard
Sigma-Aldrich
磷酸, BioUltra, ≥85% (T)
Sigma-Aldrich
磷酸, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥85%